Josiah M. Slotnick is a member of Cahill's corporate practice group.
Joe represents leading investment banking firms, commercial banks and public and private issuers,
with a focus on leveraged finance transactions involving both syndicated
institutional loans and asset based loans and new issuance of secured
and unsecured high-yield debt securities. He represented the financing
sources in a number of recent acquisitions, including the merger of Valeant Pharmaceuticals and Biovail Corporation, inVentiv Health by
Thomas H. Lee Partners, Columbian Chemicals by Aditya Birla Group, the
Gymboree Corporation by affiliates of Bain Capital Partners and several
landmark leveraged buyouts of the LBO boom, including hospital-operator
HCA, Travelport, Biomet and Lyondell Chemical Company. He also represents investment banks
and financial advisors in connection with debt refinancings and
comprehensive out-of-court debt restructurings, such as the recent $4.5
billion refinancing of DaVita and $5 billion exit financing for
LyondellBasell's 2010 emergence from Chapter 11.
Joe works on both the bank and high-yield bond sides of acquisition
financings and refinancings and has practiced in a variety of industries
such as healthcare, life sciences, pharmaceuticals, financial services,
technology, chemicals, telecom and gaming.